CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma - Wikidata - thesis-toulmin - TriplyDB

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

http://www.wikidata.org/entity/Q36093810

about

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest Cell cycle proteins as promising targets in cancer therapy Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.CDK4 expression in chordoma: A potential therapeutic target.Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.

P2860

Q33759276-40EB0B86-69B7-44F6-A86A-A6A65D5903A7 Q37693690-5A37A6FD-D70F-4E29-BF62-E07D27FE0604 Q38371672-E7A5C565-3AA5-4CF6-930C-04270E723F9F Q38718679-40E15CFD-319A-4FCE-8597-84A18E23430A Q38723383-6D72F19C-53CB-414F-A4D0-E88CF19BAE57 Q47294507-F7B91DD7-40CA-4599-A21F-00B84D13E152 Q47384424-7345C6CE-152D-4657-A2E7-5481C49C9229 Q52579552-55D9EAE9-CADB-4CB0-BB69-1F8E15EC5A12 Q55710176-3908A77B-4426-4588-BC3E-0924AB5DCF13

P2860

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

http://www.wikidata.org/entity/Q36093810

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@ast

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@en

type

label

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@ast

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@en

prefLabel

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@ast

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@en

P1433

Q36093810-BF778981-F5A3-499B-85B4-33E4F1048A9A

P1476

Q36093810-636B5AFF-541D-4D83-AD9C-932DC7C54011

P2093

Q36093810-730CE770-7B2C-4F49-8BB2-7FCF7C0322EC

Q36093810-80BF43F7-FE46-44F5-A3BF-42A29B122C26

Q36093810-BB26ABC5-F930-4B69-993A-0B3891AC60D9

Q36093810-DE5DC41A-9373-4B89-B70F-7F3F0DBB6C66

P2860

Q36093810-010D2C94-36B2-42DF-913B-13BDFCADE5EA

Q36093810-043EABF5-1E31-49D6-975F-EF9C3EAD2A49

Q36093810-12F6CE07-63A0-404B-8E2F-D48B2639A105

Q36093810-1FBA667E-9E3D-43C7-ACD5-EAA71E7B1ED6

Q36093810-2B205899-AD79-423B-B025-157697C0676D

Q36093810-35C0E336-09B4-44C1-A5C2-E49B394E895B

Q36093810-441F034C-127E-4680-B728-FB20D4E07FAE

Q36093810-46A464E1-3D49-45EA-B756-71E4ADE9E186

Q36093810-58C07657-2392-4973-9B74-8E2C545297F5

Q36093810-5989490C-465B-43B2-B503-27300834EDCA

P304

Q36093810-C02F95C5-717A-4E83-9D39-639F21C90A3D

P31

Q36093810-D09FCC10-27EA-42AE-870C-5C3A158FDF18

P356

Q36093810-89927AC2-FCBF-4F89-A1F2-2A8EF7628479

P407

Q36093810-474E0D82-09AC-4872-B205-E8A82F028F12

P433

Q36093810-7C0CEBE3-3CF1-4482-AA66-4A48DC703615

P478

Q36093810-EE721E6A-E7AC-49F3-B18C-F0E1A980A941

P50

Q36093810-0610973C-009B-425A-B8E5-3B2BF77E6DD2

Q36093810-54DD831D-3DC9-4897-9F6E-B799C5B101FE

P577

Q36093810-D065F1CE-66DF-423F-B658-19367550ECD9

P698

Q36093810-CB470A3B-D6C0-4216-8828-75E67C1F134D

P932

Q36093810-9E2354F8-DF4C-4075-8CD4-68DB2A0177DC

P356

1078-0432.CCR-14-2955

P1433

Clinical Cancer Research

P1476

CDK4 Amplification Reduces Sen ...... sion-Positive Rhabdomyosarcoma

@en

P2093

Frederic G Barr

http://www.w3.org/2001/XMLSchema#string

Mary E Olanich

http://www.w3.org/2001/XMLSchema#string

Wenyue Sun

http://www.w3.org/2001/XMLSchema#string

Zied Abdullaev

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Cell cycle, CDKs and cancer: a changing paradigm

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase

Cellular senescence and tumor suppressor gene p16

E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Cell cycle kinases as therapeutic targets for cancer

Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas

Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances

P304

4947-4959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-2955

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Stephen M. Hewitt

Svetlana D. Pack

P577

2015-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25810375

http://www.w3.org/2001/XMLSchema#string

P932

4583342

http://www.w3.org/2001/XMLSchema#string